Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
J Proteome Res. 2010 Jun 4;9(6):2798-808. doi: 10.1021/pr100063r.
Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory lung disease associated with progressive obstruction of airflow affecting peripheral airways. The proteomic analysis highlights ways to identify novel biomarkers for diagnosis, therapy, and prognosis in COPD. Human samples, for example, lung tissue, bronchoalveolar lavage, sputum, and serum, have been used for COPD proteomic research, each with its own merits and demerits. In the present review, we aimed at discussing the feasibility of clinical studies on COPD proteomics and the potential candidates for COPD biomarkers detected in human samples that are sensitive to the progress of COPD, disease-specific to COPD, and associated with the status of the patients. There is an increasing need to be able to perform proteomic studies on patients with COPD that describe the association with disease specificity, severity, progress, and prognosis as well as monitor the efficacy of therapies. There is an urgent need to establish and clarify the criteria for subjects including controls and data analysis and standardize the study design, methodology, and process as this is vital when designing prospective clinical studies on COPD. It is important to clarify the source of the samples, the efficiency, and quality when dealing with large amount of candidates and the specificity of biomarkers according to the severity, therapeutic effects, progress, and prognosis of the disease.
慢性阻塞性肺疾病（COPD）是一种慢性炎症性肺部疾病，与影响外周气道的气流进行性阻塞有关。蛋白质组学分析突出了识别 COPD 诊断、治疗和预后的新型生物标志物的方法。例如，已经使用人类样本（如肺组织、支气管肺泡灌洗、痰和血清）进行 COPD 蛋白质组学研究，每种样本都有其自身的优点和缺点。在本综述中，我们旨在讨论 COPD 蛋白质组学临床研究的可行性，以及在人类样本中检测到的对 COPD 进展敏感、具有 COPD 特异性和与患者状况相关的 COPD 生物标志物的潜在候选者。越来越需要能够对 COPD 患者进行蛋白质组学研究，以描述与疾病特异性、严重程度、进展和预后的关联，并监测治疗效果。迫切需要建立和澄清包括对照和数据分析在内的研究对象的标准，并规范研究设计、方法和流程，因为这对于设计 COPD 的前瞻性临床研究至关重要。重要的是要根据疾病的严重程度、治疗效果、进展和预后，明确处理大量候选者和生物标志物特异性时样本的来源、效率和质量。
